Awaiting development: Guidance and quality standards

Showing 171 to 180 of 283

Guidance and quality standards awaiting development
Title	Type
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
Orforglipron for managing overweight and obesity [ID6516]	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance